Vitamin and supplement retailer GNC Holdings has lowered its outlook for 2015 after a disappointing third quarter, news that sent its stock shares tumbling for the second time in a week.

GNC officials say they now see earnings per share for 2015 to be in the range of $2.85 to $2.90, down from their earlier estimate of $3 to $3.10. Reported earnings of 76 cents per share for the third quarter fell short of the 83 cents analysts were looking for.

“In hindsight, clearly our expectations were set too high,” said CEO Mike Archbold during the Downtown-based company’s quarterly financial media telephone briefing Thursday.

Customers did not respond to a promotional strategy of bundling products to their specific health and wellness needs, Mr. Archbold acknowledged. “We have moved fast and at times perhaps faster than the customers could adjust.”

Advertise with us

For the third quarter, net income showed a sharp decline from the same period in 2014, from $64.3 million to $45.8 million, after the company took a $28.3 million pre-tax impairment associated with its investment in Discount Supplements. GNC acquired the United Kingdom sports nutrition e-commerce retailer in 2013.

GNC reported revenue of $672.2 million over the three months, a 2.4 percent increase over the $656.3 million for the third quarter of 2014 but short of analyst estimates of $684 million. Same store sales, or sales in stores open at least a year, were down 0.3 percent.

While the short-term results were disappointing, Mr. Archbold said the strategies of targeted marketing, strengthening the franchisee sector and moving away from unprofitable promotions “are the right things to do,” adding later “the good news is that there are actually a lot of good indicators of long-term success.”

GNC could use some good news after Oregon’s attorney general filed suit last week, accusing the company of selling supplements made with illegal ingredients. News of that suit sent GNC stock falling 21 percent to $34.50.

After Thursday’s financial briefing, the stock took an even bigger hit, trading at $27.40 at one point compared with $42.27 just three weeks earlier.

Advertise with us

Mr. Archbold addressed the Oregon lawsuit allegations head on, saying the products were made by a third party and that GNC removed them from the shelves as soon as the U.S. Food and Drug Administration questioned the products.

The Oregon suit marks the second time this year that a state attorney general’s office has questioned GNC products.

In February, New York Attorney General Eric Schneiderman sent cease-and-desist letters to GNC, Target, Walgreens and Walmart alleging they had sold herbal supplements with ingredients not listed on the labels.

GNC, which questioned the AG office’s testing methodology, agreed in March to perform additional testing on its products that will exceed FDA standards while maintaining the company had followed all regulatory requirements and its products were safe all along.

On Thursday, Mr. Archbold said civil lawsuits filed in light of Mr. Schneiderman’s initial cease-and-desist order have either been dropped or have removed GNC from the complaint.

Advertise with us

He also said GNC is organizing a coalition of firms involved at each step of the production process, from raw materials to retail, that would include annual facility certifications.

“We believe this will help to reduce the amount of unfounded and meritless allegations.”

GNC shares closed Thursday at $ 28.24, down $10.40 or almost 27 percent.

Steve Twedt: stwedt@post-gazette.com or 412-263-1963.